Literature DB >> 22798037

Challenges with developing in vitro dissolution tests for orally inhaled products (OIPs).

Trevor Riley1, David Christopher, Jan Arp, Andrea Casazza, Agnes Colombani, Andrew Cooper, Monisha Dey, Janet Maas, Jolyon Mitchell, Maria Reiners, Nastaran Sigari, Terrence Tougas, Svetlana Lyapustina.   

Abstract

The purpose of this article is to review the suitability of the analytical and statistical techniques that have thus far been developed to assess the dissolution behavior of particles in the respirable aerodynamic size range, as generated by orally inhaled products (OIPs) such as metered-dose inhalers and dry powder inhalers. The review encompasses all analytical techniques publicized to date, namely, those using paddle-over-disk USP 2 dissolution apparatus, flow-through cell dissolution apparatus, and diffusion cell apparatus. The available techniques may have research value for both industry and academia, especially when developing modified-release formulations. The choice of a method should be guided by the question(s) that the research strives to answer, as well as by the strengths and weaknesses of the available techniques. There is still insufficient knowledge, however, for translating the dissolution data into statements about quality, performance, safety, or efficacy of OIPs in general. Any attempts to standardize a dissolution method for compendial inclusion or compendial use would therefore be premature. This review reinforces and expands on the 2008 stimulus article of the USP Inhalation Ad Hoc Advisory Panel, which "could not find compelling evidence suggesting that such dissolution testing is kinetically and/or clinically crucial for currently approved inhalation drug products."

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22798037      PMCID: PMC3429693          DOI: 10.1208/s12249-012-9822-3

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  20 in total

Review 1.  Modeling and comparison of dissolution profiles.

Authors:  P Costa; J M Sousa Lobo
Journal:  Eur J Pharm Sci       Date:  2001-05       Impact factor: 4.384

Review 2.  Analysis of cascade impactor mass distributions.

Authors:  Craig Dunbar; Jolyon Mitchell
Journal:  J Aerosol Med       Date:  2005

3.  On the use of the Weibull function for the discernment of drug release mechanisms.

Authors:  Vasiliki Papadopoulou; Kosmas Kosmidis; Marilena Vlachou; Panos Macheras
Journal:  Int J Pharm       Date:  2005-12-20       Impact factor: 5.875

Review 4.  New developments in corticosteroids.

Authors:  Günther Hochhaus
Journal:  Proc Am Thorac Soc       Date:  2004

Review 5.  In vitro/in vivo comparisons in pulmonary drug delivery.

Authors:  Stephen P Newman; Hak-Kim Chan
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2008-03       Impact factor: 2.849

6.  FIP/AAPS joint workshop report: dissolution/in vitro release testing of novel/special dosage forms.

Authors:  Cynthia K Brown; Horst Dieter Friedel; Amy R Barker; Lucinda F Buhse; Susanne Keitel; Todd L Cecil; Johannes Kraemer; J Michael Morris; Christos Reppas; Mary P Stickelmeyer; Chikako Yomota; Vinod P Shah
Journal:  AAPS PharmSciTech       Date:  2011-06-18       Impact factor: 3.246

7.  Pharmacokinetic/pharmacodynamic aspects of aerosol therapy using glucocorticoids as a model.

Authors:  G Hochhaus; H Möllmann; H Derendorf; R J Gonzalez-Rothi
Journal:  J Clin Pharmacol       Date:  1997-10       Impact factor: 3.126

8.  Draft guidance for industry extended-release solid oral dosage forms. Development, evaluation and application of in vitro-in vivo correlations.

Authors:  H Malinowski; P Marroum; V R Uppoor; W Gillespie; H Y Ahn; P Lockwood; J Henderson; R Baweja; M Hossain; N Fleischer; L Tillman; A Hussain; V Shah; A Dorantes; R Zhu; H Sun; K Kumi; S Machado; V Tammara; T E Ong-Chen; H Mahayni; L Lesko; R Williams
Journal:  Adv Exp Med Biol       Date:  1997       Impact factor: 2.622

Review 9.  Pulmonary surfactant in health and human lung diseases: state of the art.

Authors:  M Griese
Journal:  Eur Respir J       Date:  1999-06       Impact factor: 16.671

10.  Laser-ablated nanofunctional polymers for the formulation of slow-release powders for dry powder inhalers: physicochemical characterization and slow-release characteristics.

Authors:  Intira Coowanitwong; Vikram Arya; Gina Patel; Won-Seok Kim; Valentin Craciun; James R Rocca; Rajiv Singh; Günther Hochhaus
Journal:  J Pharm Pharmacol       Date:  2007-11       Impact factor: 3.765

View more
  21 in total

Review 1.  In Vitro Testing for Orally Inhaled Products: Developments in Science-Based Regulatory Approaches.

Authors:  Ben Forbes; Per Bäckman; David Christopher; Myrna Dolovich; Bing V Li; Beth Morgan
Journal:  AAPS J       Date:  2015-05-05       Impact factor: 4.009

2.  In Vivo-Relevant Transwell Dish-Based Dissolution Testing for Orally Inhaled Corticosteroid Products.

Authors:  Masahiro Sakagami; Hua Li; Jügen Venitz
Journal:  Pharm Res       Date:  2019-05-09       Impact factor: 4.200

Review 3.  Advances in metered dose inhaler technology: formulation development.

Authors:  Paul B Myrdal; Poonam Sheth; Stephen W Stein
Journal:  AAPS PharmSciTech       Date:  2014-01-23       Impact factor: 3.246

4.  Dissolution testing of powders for inhalation: influence of particle deposition and modeling of dissolution profiles.

Authors:  Sabine May; Birte Jensen; Claudius Weiler; Markus Wolkenhauer; Marc Schneider; Claus-Michael Lehr
Journal:  Pharm Res       Date:  2014-05-23       Impact factor: 4.200

5.  In vitro assessment of arsenic mobility in historical mine waste dust using simulated lung fluid.

Authors:  Rachael Martin; Kim Dowling; Scott Nankervis; Dora Pearce; Singarayer Florentine; Stafford McKnight
Journal:  Environ Geochem Health       Date:  2017-05-12       Impact factor: 4.609

6.  Effects of the antibiotic component on in-vitro bacterial killing, physico-chemical properties, aerosolization and dissolution of a ternary-combinational inhalation powder formulation of antibiotics for pan-drug resistant Gram-negative lung infections.

Authors:  Sharad Mangal; Jiayang Huang; Nivedita Shetty; Heejun Park; Yu-Wei Lin; Heidi H Yu; Dmitry Zemlyanov; Tony Velkov; Jian Li; Qi Tony Zhou
Journal:  Int J Pharm       Date:  2019-02-21       Impact factor: 5.875

7.  Inhalable Clarithromycin Microparticles for Treatment of Respiratory Infections.

Authors:  Frantiescoli Dimer; Cristiane de Souza Carvalho-Wodarz; Jörg Haupenthal; Rolf Hartmann; Claus-Michael Lehr
Journal:  Pharm Res       Date:  2015-06-26       Impact factor: 4.200

8.  Polymeric Microparticles: Synthesis, Characterization and In Vitro Evaluation for Pulmonary Delivery of Rifampicin.

Authors:  Faiqa Falak Naz; Kifayat Ullah Shah; Zahid Rasul Niazi; Mansoor Zaman; Vuanghao Lim; Mulham Alfatama
Journal:  Polymers (Basel)       Date:  2022-06-19       Impact factor: 4.967

9.  Effects of Surface Composition on the Aerosolisation and Dissolution of Inhaled Antibiotic Combination Powders Consisting of Colistin and Rifampicin.

Authors:  Wenbo Wang; Qi Tony Zhou; Si-Ping Sun; John A Denman; Thomas R Gengenbach; Nicolas Barraud; Scott A Rice; Jian Li; Mingshi Yang; Hak-Kim Chan
Journal:  AAPS J       Date:  2015-11-24       Impact factor: 4.009

10.  Toxicity of orally inhaled drug formulations at the alveolar barrier: parameters for initial biological screening.

Authors:  Eleonore Fröhlich
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.